Abstract
Erythropoiesis-stimulating agents (ESAs) are administered routinely to manage anemia in patients with chronic kidney disease (CKD); however, the optimal target hemoglobin level remains uncertain. In this meta-analysis of 17 randomized trials, researchers evaluate the effect of different hemoglobin targets on …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
